Previous Article | Next Article 
J Virol, August 1998, p. 6608-6613, Vol. 72, No. 8
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
In Vivo Effects of Mutations in Woodchuck
Hepatitis Virus Enhancer II
Yu
Wei,1,
Bud
Tennant,2 and
Don
Ganem1,3,*
Departments of Microbiology and
Medicine1 and
Howard Hughes Medical
Institute,3 University of California, San
Francisco, California 94143, and
Department of Clinical
Sciences, College of Veterinary Medicine, Cornell University,
Ithaca, New York 148522
Received 5 March 1998/Accepted 13 May 1998
 |
ABSTRACT |
Woodchuck hepatitis virus (WHV) enhancer II (EnII) is located
upstream of the major pregenomic RNA promoter and is thought to play an
important role in the insertional activation of the N-myc2
gene during WHV hepatocarcinogenesis. WHV EnII is
recognized by at least three host transcription factors: HNF-1, HNF-4,
and Oct-1. Here, the roles of these EnII-binding factors in viral transcription and replication have been further examined. In HepG2 cells transiently transfected with a chloramphenicol acetyltransferase (CAT) gene whose expression is dependent upon EnII, mutations in either
the HNF-1 or the HNF-4 site strongly reduced CAT activity, while
ablation of the Oct-1 site decreased CAT expression only twofold.
Mutations in more than one site completely abolished reporter
expression. These same mutations were also tested in an overlength WHV
genome for their impact on viral replication and gene expression. In
transfected HepG2 cells, lesions in the HNF-1 site inactivated
pregenomic RNA expression and viral reverse transcription, with only
minimal effects on the expression of other viral mRNAs. By contrast,
Oct-1 site lesions had no effect on either viral RNA synthesis or DNA
replication, and HNF-4 site lesions produced a modest reduction of
pregenomic RNA but had no impact on viral DNA synthesis. Testing of the
mutants in susceptible woodchucks revealed that, as expected, viruses
with lesions in the HNF-1 site were nearly noninfectious, while mutants
with lesions at the Oct-1 site were fully replication competent. HNF-4
site mutants were replication competent but may display reduced levels of replication in the intact animal host. We conclude that (i) EnII is
primarily devoted to the regulation of pregenomic RNA in WHV, (ii)
HNF-1 is essential for EnII function in vivo, and (iii) HNF-4 plays
a demonstrable but adjunctive role in EnII function.
 |
INTRODUCTION |
Hepatitis B viruses (HBVs;
hepadnaviruses) are small, enveloped DNA viruses that
produce persistent hepatic infections and are strongly
associated with the development of hepatocellular carcinoma
(5). The viral genome is a partially duplex, relaxed circular species of approximately 3 kb that replicates within cells via
reverse transcription. Upon entry into cells, the viral genome is
converted into covalently closed circular DNA that serves as the template for the synthesis of subgenomic RNA and pregenomic RNA
(pgRNA) by host RNA polymerase (19). Studies on
transcription of human HBV have shown that this step is
controlled by regulatory elements that include four promoters and two
enhancers (1, 11, 13, 15, 16, 24, 26, 27). The preS, S, and
X promoters drive the transcription of subgenomic RNAs encoding the envelope and X proteins. The C promoter controls the production of
the pgRNA that encodes the core protein and polymerase and that also serves as the template for viral reverse transcription.
Two enhancers, enhancer I (EnI) and EnII, located upstream
of the HBV X and C promoters, respectively, have been shown to be
capable of upregulating homologous and heterologous promoters in
transient transfection (15, 21, 29). EnI has been proposed to be widely involved in the regulation of HBV transcription
(18). However, despite the shared genomic organization and
replication cycle of mammalian hepadnaviruses, EnI activity
has not been found in other viruses of the family (2, 22).
EnII is known to enhance the C promoter in transient assays, suggesting
that it might regulate the transcription of pgRNA (18,
28). The expression of pgRNA is highly liver specific, a
fact that correlates well with the known liver specificity of EnII
activity (28). Thus, it is attractive to speculate that
EnII, together with the C promoter, may account for the liver-specific
expression of pgRNA that determines (at least in part) the
hepatotropism of hepadnaviruses (6, 14, 28).
Woodchuck hepatitis virus (WHV) is a mammalian hepadnavirus
that is closely related to HBV and is strikingly oncogenic in its
natural host (12, 20). Analyses of WHV-induced woodchuck hepatocellular carcinomas have demonstrated that activation of the
proto-oncogene N-myc2 by viral DNA insertion is commonly
involved in carcinogenesis (4, 7, 25). Our studies of viral
DNA sequences in N-myc2 activation suggested that the region
corresponding to HBV EnII played a major role in the activation
(22). Accordingly, we and others have mapped and
characterized EnII in WHV (3, 23). The activity of WHV EnII
maps to an 88-nucleotide DNA fragment (nucleotides 1772 to 1859)
upstream from the transcription initiation site of pgRNA.
Biochemical and genetic studies have identified three host
transcription factors that recognize elements within this region: the
liver-enriched factors HNF-1 and HNF-4 and the ubiquitous factor Oct-1
(23). Deletion analyses suggested that HNF-1 and HNF-4 are
the main contributors to the EnII activity in transient assays and
together account for its strong liver specificity.
Most analyses of HBV and WHV enhancer activity have been carried out by
using transient assays with cell lines transfected with artificial
reporter constructs. The role(s) of the host transcription factors that
regulate viral En elements in viral replication in vivo have not been
fully defined in the mammalian viruses, although efforts in this
direction have been made for duck HBV (9). In this study, we
undertook in vitro and in vivo analyses of the role of WHV EnII in the
viral life cycle. First, we introduced mutations in WHV EnII that
abolish the binding of HNF-1, HNF-4, or Oct-1 to the element and
assessed the effects of these mutations, singly and in combination, on
EnII activity, as assayed on a chloramphenicol acetyltransferase
(CAT) reporter driven by a minimal promoter linked to EnII. We
then constructed 1.5-mer WHV genomes bearing these mutations and tested
their abilities to transcribe and replicate viral DNA in cultured
cells. Finally, selected mutant genomes were injected intrahepatically
into woodchucks to investigate their replication competence in
vivo. We show here that EnII primarily governs the production of
pgRNA in vivo and that HNF-1 is required for this activity.
 |
MATERIALS AND METHODS |
Plasmids.
All of the WHV EnII mutants we used are based on
pBluescript II KS+ (Stratagene). The fragment from nucleotide 1697 to
nucleotide 1919 (the nucleotide sequence and numbering are according to
Kodama et al. [8]) encompassing EnII was prepared by
PCR on the template WHV monomer (pWHVmono), in which 5'-end primer
WBam1697-1711 (5'-GACTGGATCCCTCCGGTCCGTGTTG-3') and 3'-end
primer WBam1919-1905 (5'-GACTGGATCCTCGCATGCATTTATG-3') were used. The PCR product was gel purified and cloned into the BamHI site in pBSKS+. The resulting plasmid,
pW1697-1919WT, served as a template for PCR to introduce
mutations into the EnII region.
To mutate transcriptional factor binding sites, PCR was performed in
two rounds. In the first round, two independent PCRs were carried out
with two pairs of primers. The primers were designed such that the
3'-end primer of one pair has the complementary sequence of the 5'-end
primer of another pair, and desired mutations were introduced into
these two primers. To mutate the HNF-4 binding site (designated the A
site), 5'-end primer WBam1697-1711 and 3'-end primer IIA/AS
(5'-GATCTTTTATATAAGGAGTCCAcAGaTCCTTACTTGG-3' [nucleotides
1833 to 1797; nucleotides in lowercase represent mutations] were used
in one PCR, while 5'-end primer IIA/S
(5'-CATGCCAAGTAAGGAtCTgTGGACTCCTTATATAAAA-3' [nucleotides
1793 to 1829]) was paired with 3'-end primer WBam1919-1905. To mutate
the HNF-1 binding site (designated the B site), primer WBam1697-1711
was paired with primer IIB/AS
(5'-GCCCTCCTCCCATTTcGTgAggAgcTGATCTTT-3' [nucleotides
1859 to 1827]) and primer IIB/S
(5'-ATAAAAGATCAgcTccTcACgAAATGGGAGGAG-3' [nucleotides 1824 to 1856]) was paired with primer WBam1919-1905. To mutate the Oct-1
binding site (designated the C site), primers WBam1697-1711 and IIC/AS
(5'-GCATGCCAAGTTGACGgTTgGCgTGCCAGGAGACAAAG-3' [nucleotides
1797 to 1760]) were paired, while primers IIC/S
(5'-GAACTTTGTCTCCTGGCAcGCcAAcCGTCAACTTGGC-3' [nucleotides
1757 to 1793]) and WBam1919-1905 were paired. The products of the
first-round PCR were pooled and used as template DNA in second-round
PCRs in which primers WBam1697-1711 and WBam1919-1905 were used. The
final PCR products were then gel purified, digested with
BamHI, and cloned into pBSKS+ cut with BamHI,
resulting in plasmids pW1697-1919IIA(
), pW1697-1919IIB(
), and
pW1697-1919IIC(
).
To mutate both the HNF-4 and HNF-1 sites, pW1697-1919IIB(

) was used
as the template in the first-round PCRs, in which primer
WBam1697-1711
paired with primer IIA/AS and primer IIA/S paired
with primer
WBam1991-1905 were used. To mutate both the HNF-4
and Oct-1 sites,
pW1697-1919IIC(

) was used as the template in
PCRs in which primer
WBam1697-1711 paired with primer IIA/AS and
primer IIA/S paired with
primer WBam1991-1905 were used. To mutate
both the HNF-1 and
Oct-1 sites, pW1697-1919IIB was used as the
template in PCRs in which
primer WBam1697-1711 paired with primer
IIC/AS and primer IIC/S paired
with primer WBam1919-1905 were
used. The PCR products were pooled
and used as templates in second-round
PCRs in which primer
WBam1697-1711 was paired with primer WBam1919-1905.
The final
PCR products were cloned into pBSKS+, resulting in plasmids
pW1697-1919IIAB(

), pW1697-1919IIAC(

), and pW1697-1919IIBC(

).
To mutate the triple binding sites, pW1697-1919IIBC(

) was amplified
in PCRs in which primer WBam1697-1711 paired with primer
IIA/AS and
primer IIA/S paired with primer WBam1919-1905 were
used.
The second-round PCR was performed by using the first-round
PCR
products as the template and WBam1697-1711 and WBam1919-1905
as the primers. The final PCR product was cloned into a
pBSKS+
vector, giving rise to plasmid pW1697-1919IIABC(

).
Plasmids EnIIWTE1bCAT, EnIIA(

)E1bCAT, EnIIB(

)E1bCAT,
EnIIC(

)E1bCAT, EnIIAB(

)E1bCAT, EnIIAC(

)E1bCAT,
EnIIBC(

)E1bCAT,
and EnIIABC(

)E1bCAT were constructed by
cloning the insert fragments
of pW1697-1919WT,
pW1697-1919IIA(

), pW1697-1919IIB(

), pW1697-1919IIC(

),
pW1697-1919IIAB(

), pW1697-1919IIAC(

), pW1697-1919IIBC(

) and
pW1697-1919IIABC(

) into the
XhoI and
XbaI sites
in E1bCAT, which
has been described elsewhere (
23).
The
RsrII-
NsiI fragments (nucleotides 1701 to
1914) of pW1697-1919 mutants were cut out and cloned into pWHVmono cut
with
RsrII and
NsiI. The monomer mutants, as well
as the wild type
(WT), were then cut with
ApaI and
EcoRI. The
ApaI-
EcoRI fragments
(nucleotides 891 to 3320) were gel purified and cloned into the
ApaI and
EcoRI sites in pBSKS+. The pApaI-EcoRI
constructs were
then digested with
EcoRI and
SmaI
and used as vectors to receive
the
EcoRI-
BglII
(nucleotides 1 to 2531) fragments generated from
the monomer mutants
(the termini from
BglII digestion having been
blunted by
treatment with Klenow polymerase). The resulting 1.5-mer
WHV genomes
contain two copies of the region from nucleotide 891
to nucleotide
2531.
The nucleotide sequences of the fragments generated by PCR were
confirmed by conventional dideoxy sequencing.
EMSA.
The fragments used as probes for electrophoretic
mobility shift assay (EMSA) were generated by PCRs in which
pW1697-1919WT, -IIA(
), -IIB(
), -IIC(
), -IIAB(
), IIAC(
),
-IIBC(
), and -IIABC(
) were amplified with Taq polymerase
and primers with the sequences 5'-CTTTGTCTCCTGGC-3'
(nucleotides 1760 to 1773) and 5'-GCCCTCCTCCCATT-3' (nucleotides 1859 to 1846). The fragments (spanning nucleotides 1760 to 1859) were then labeled with T4 polynucleotide kinase and
[32P]ATP and incubated with nuclear extracts from HepG2
cells as previously described (23).
Transfection of HepG2 cells and CAT assay.
HepG2 cells were
cultured in Dulbecco modified Eagle medium supplemented with 10%
bovine serum and penicillin-streptomycin. Transfection was performed by
the calcium phosphate coprecipitation method. At 16 h after
transfection, cells were washed twice with phosphate-buffered saline
without calcium and magnesium and incubated for another 24 h. The
CAT assay was carried out as previously described (23). All
assays were performed in duplicate, and each experiment was replicated
at least three times.
Nucleic acid analysis.
Total RNA was isolated from
transfected HepG2 cells with RNAzol (TEL-TEST), electrophoresed through
a standard 1% agarose-2.2 M formaldehyde gel, and transferred to a
Hybond N membrane (Amersham). Nucleic acids in cytoplasmic
nucleocapsids were prepared as previously described (10, 17)
and analyzed by electrophoresis, transfer into Hybond N+ (Amersham) in
0.4 N NaOH, and hybridization with WHV genomic DNA. To prepare DNA from
woodchucks, liver biopsy samples were incubated in 10 mM Tris-HCl (pH
8.0)-10 mM NaCl-10 mM EDTA-1% sodium dodecyl sulfate-120-µg/ml
proteinase K at 4°C overnight, phenol extracted three times,
chloroform extracted once, and ethanol precipitated. DNA was digested
with PvuII and subjected to Southern blotting.
In situ transfection of woodchucks.
The experimental
woodchucks were born and raised in laboratory animal facilities
and, prior to inoculation, were negative for serologic markers of
infection (woodchuck hepatitis surface antigen [WHsAg],
anti-woodchuck hepatitis core antigen antibody [anti-WHc], and
anti-WHsAg antibody). DNA of the 1.5-mer WHV genome was
prepared by using the Qiagen plasmid kit. For transfection in vivo,
laparotomies were performed under general anesthesia and 50 µg
of DNA (suspended in 0.5 ml of phosphate-buffered saline was injected
at multiple sites into the parenchyma of the left lateral lobe of the
liver. Groups of three animals were transfected with the mutant
EnIIA(
), EnIIB(
), EnIIC(
), or EnIIABC(
) or the WT 1.5-mer
WHV genome.
Serological assay.
Serum samples were collected serially,
beginning 4 weeks postransfection, at ca. 2-week intervals for a total
of 7 months. The sera were tested for the presence of WHsAg and
anti-WHc by using enzyme-linked immunosorbent assays (1a).
At 13 weeks after transfection, the animals were anesthetized and
percutaneous needle biopsies of the liver were performed under
ultrasound guidance.
 |
RESULTS AND DISCUSSION |
Effect of EnII mutations in transient transfection
assays.
In previous studies (23), we mapped
WHV EnII to an 88-bp fragment (nucleotides 1772 to 1859) and
demonstrated the binding of transcription factors Oct-1, HNF-1, and
HNF-4 to subregions designated IIC, IIB, and IIA, respectively (Fig.
1A). In preliminary deletion analyses
using CAT reporter genes driven by EnII and a minimal TATA box, we
showed that the absence of the binding site for Oct-1 reduced EnII
activity only twofold, while more extensive deletions involving the A
and B sites resulted in more dramatic losses of activity
(23).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 1.
Mutations abolishing binding of transcription factors to
WHV EnII. (A) schematic representation of the EnII region. The mutated
nucleotides in the binding sites of Oct-1, HNF-4, and HNF-1 are shown
below the diagram. (B) Mutations block binding of the factors. The
indicated WT and mutant labeled EnII fragments were incubated with
HepG2 nuclear extract and then examined by EMSA as described in
Materials and Methods. IIA( ), HNF-4 binding site mutated; IIB( ),
HNF-1 binding site mutated; IIC( ), Oct-1 binding site mutated.
|
|
To assess more precisely the effects of these transcription factors on
the function of WHV EnII, we constructed point mutations
in EnII which
selectively destroyed the binding sites for Oct-1,
HNF-1, and HNF-4.
(The mutations generated were chosen so as not
to alter the coding
sequence of the overlapping X gene, so that
these lesions could later
be studied in the context of the intact
genome [Fig.
1A].) The
mutations were built back into EnII either
singly, pairwise, or as the
triple mutant; the resulting mutant
EnII fragments were tested for the
ability to bind to host nuclear
factors by EMSA. WT or mutant EnII
fragments were end labeled
with [
32P]ATP and incubated
with HepG2 nuclear extract; complexes were
then fractionated by
nondenaturing acrylamide gel electrophoresis.
Figure
1B shows the
result of this analysis. As previously demonstrated
(
23),
three complexes involving HNF-1, Oct-1, and HNF-4 were
formed on the WT
EnII fragment (lane WT). The mutations in the
HNF-4, HNF-1, and Oct-1
binding sites selectively blocked the
binding of the corresponding
factors [lanes EnIIA(

), EnIIB(

),
and EnIIC(

)]. Similarly, the
expected combinations of shifted
complexes were disrupted by the
double and triple mutations [lanes
EnIIAB(

), EnIIAC(

), EnIIBC(

),
and EnIIABC(

)]. These results
confirmed that the mutations
introduced into each site inactivated
the binding of the corresponding
factor to EnII DNA.
To test the effects of the mutations on EnII activity, we cloned these
same mutant EnII DNA segments upstream of an E1b TATA
box driving the
CAT gene and transfected the constructs into HepG2
cells; the parental
E1b TATA-CAT vector was transfected in parallel.
The human growth
hormone gene (driven by the thymidine kinase
promoter of herpes simplex
virus) was used as an internal control
for transfection efficiency.
After 48 h, cells were assayed for
CAT activity. The values in
Fig.
2 represent the mean results
of
three independent experiments. As previously described (
23),
WT EnII strongly enhanced the minimal E1B promoter when linked
to it in
cis (Fig.
2). Knockout of the HNF-4 binding site in EnII
strongly decreased CAT activity (14-fold), while the mutations
in the
HNF-1 binding site resulted in almost complete inactivation
of EnII
function. In contrast, an only twofold drop in CAT activity
was
observed in the transfection with the construct bearing mutations
in
the Oct-1 binding site (Fig.
2). All combination (double or
triple)
mutants rendered EnII unable to enhance the minimal promoter
activity
more than twofold (Fig.
2).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
Effects of EnII mutations on CAT reporter gene activity
in transient transfection assays. EnII mutant and WT DNA segments were
cloned into an E1b TATA-CAT vector. The results of CAT assay were
normalized to the level of CAT activity of E1b TATA-CAT (arbitrarily
set at 1.0).
|
|
These data are in good accord with our earlier deletion
analyses (
23) and confirm and extend those results. Because
of the
central position of the HNF-4 binding site in EnII (Fig.
1A),
our earlier deletion studies were unable to assess the impact
of a solo
mutation in this element. The present findings reveal
that HNF-4 plays
an important role in the regulation of EnII function,
at least in
transient reporter assays using heterologous promoters.
HNF-1 is required for the production of pgRNA in HepG2
cells.
To investigate the effects of these mutations on viral
replication in cultured cells, we recombined the mutations into
overlength (1.5-mer) viral genomes and transfected them into HepG2
cells, which are known to be permissive for WHV replication
(14); WT WHV DNA transfected in parallel served as a
positive control. Three days after transfection, total cellular RNA
was examined by Northern blot hybridization with WHV DNA. The
results of three independent experiments showed that viral
genomes bearing lesions in any of the three individual sites had
only modest effects (twofold or less) on the production of the S mRNA
transcripts (Fig. 3A). In sharp contrast,
some of the lesions had pronounced effects on the production of
pgRNA. Most dramatic was the impact of mutations in the HNF-1
site: these lesions nearly totally ablated detectable pgRNA
synthesis [Fig. 3A, lanes EnIIB(
), EnIIAB(
), EnIIBC(
), and EnIIABC(
)]. Mutations in the Oct-1 site had no impact on pgRNA [or on the subgenomic transcripts; lane EnIIC(
)]. HNF-4 site mutations had a subtler phenotype: they reduced the levels of
pgRNA to levels that were roughly equimolar with the S mRNA [lanes
ENIIA(
) and EnIIAC(
)]. This phenotype, while modest, was clearly
different from that of WT WHV, in which pgRNA was clearly present
in a two- to fourfold excess over S mRNA [Fig. 3A, lanes WT and
EnIIC(
)].

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 3.
Effects of the mutations on virus expression and
replication in cultured cells. (A) Northern blot analysis of total RNA
from HepG2 cells transfected with WT or mutant 1.5-mer viral genomes,
as indicated above the gels; following transfer, the filters were
probed with 32P-labeled WHV DNA. (B) Analysis of DNA in
viral nucleocapsids from transfected cells by Southern blot
hybridization with a WHV DNA probe. Each lane corresponds to the same
transfection as in the RNA samples in panel A. ssDNA, single-stranded
DNA. Degraded plasmid DNA is shown as a loading control. (C) Control
for RNA loading, 32P-labeled
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe hybridized
to the Northern blot of panel A.
|
|
These results indicate that EnII has only modest effects on the
regulation of subgenomic mRNA transcription in the intact
viral genome.
This suggests that the C promoter is the major target
of its action, a
result that agrees well with recent studies of
Fourel et al.
(
3). HNF-1 plays a decisive role in the activation
of the C
promoter. The small impact of HNF4 site lesions on the
C promoter
contrasts markedly with the effect of such lesions
on activation of the
E1b promoter in the CAT reporter context
(Fig.
2). The reasons for this
difference are not known but could
reflect differences in TFIID binding
to the different TATA boxes
or other differences between the promoters
or the rest of the
transcription units.
To examine the consequences of these lesions for viral genomic
replication, cytoplasmic WHV nucleocapsids were prepared from
HepG2
cells transfected with the mutant and WT genomes; their
nucleic acids
were then extracted and subjected to Southern blot
analysis. As shown
in Fig.
3B, the only replication intermediates
we were able to detect
were single-stranded DNA species (lane
WT). (We do not know the
reason for the absence of duplex WHV
DNA in HepG2 cells; perhaps it is
due to the failure to complete
minus strand synthesis or to delayed
kinetics of plus strand initiation
or elongation.) As expected,
replication was normal in the Oct-1
site mutant [lane
EnIIC(

)] and was completely absent in the transfections
of viral genomes with mutations in the HNF-1 site [lanes
EnIIB(

),
EnIIAB(

), EnIIBC(

), and EnIIABC(

)].
Interestingly, viral DNA
synthesis was not affected by the mutations in
the HNF-4 binding
site [lanes EnIIA(

), and EnIIAC(

)], implying
that the modest
reduction of pgRNA levels observed in Fig.
3A had
no important
consequence for the production of core or polymerase
proteins
or of functional templates for reverse transcription. We
presume
that the concentrations of these products generated by the
mutant
genome were all above the rate-limiting concentrations for
reverse
transcription, at least in transfected HepG2 cells (but see
below).
Mutations in the HNF-1 and HNF-4 binding sites affect viral
replication in woodchucks.
HepG2 is a human hepatoma cell line and
therefore is derived from a heterologous host for WHV replication. In
addition, hepatoma cell lines (and hepatocyte cultures generally) are
known to lack many phenotypic features of fully differentiated
hepatocytes in vivo. Both of these considerations raise the possibility
that the regulation of viral replication in HepG2 cells is different from that observed in the livers of intact host animals. We therefore investigated the impact of some of the preceding EnII mutations on
viral replication in woodchucks. Given the limited availability of susceptible woodchucks, we selected the single mutations in the HNF-1, HNF-4, and Oct-1 sites and the triple mutation, which inactivates all three sites. Each of the mutant DNAs was transfected into three individual woodchucks by intrahepatic inoculation. Starting
at 4 weeks posttransfection, serum samples were collected at 2-week
intervals for 7 months and assayed for WHsAg antigenemia and
anti-WHc by enzyme immunoassay (Table 1).
As expected, all three woodchucks transfected with WT DNA
developed WHsAg antigenemia and anti-WHc and had clear evidence
of
intrahepatic viral replication (see below). All woodchucks
receiving
mutants in which the HNF-1 binding site was inactivated
[IIB(

) and
IIABC(

)] were seronegative for WHsAg for the entire
testing
period, and all but one were negative for anti-WHc as
well. It is of
note that one animal (no. 1890) displayed the extremely
late anti-WHc
development, possibly indicative of a very low-level
infection,
although subsequent analysis of this animal's liver
DNA by PCR
revealed no evidence of WHV sequences (data not shown).
Among
animals transfected with genomes lacking the Oct-1 site
[IIC(

)],
all developed anti-WHc and one had readily detectable
circulating
WHsAg. Interestingly, among the woodchucks injected
with viral DNA
containing mutations in the HNF-4 site [mutant
IIA(

)], two were
never surface antigenemic and the third was
not positive for WHsAg
until 4 months postinoculation; this animal
also displayed a prolonged
delay in the development of anti-WHc,
which did not become detectable
until 2 months after the appearance
of WHsAg (Table
1).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
WHV serology and hepatic nucleic acid analysis of
woodchucks following in situ transfection of the liver with WT and
EnII mutant WHV DNAs
|
|
To further evaluate viral replication, we performed liver biopsies on
selected woodchucks. Particular attention was paid to
the three
recipients of the HNF-4 site mutant [IIA(

)], since
this mutant had
appeared to grow well in HepG2 cells (Fig.
3B)
but less so in the
animal. DNA was extracted from biopsy samples
and examined by PCR
(Table
1). Two of the three HNF-4 site mutant
recipient animals had
viral DNA in their liver by this test, including
one that had not
displayed antigenemia. To confirm that this represented
true viral
replication and not simply residual inoculated plasmid
DNA, we
performed Southern blot analysis on DNA from the biopsy
samples. DNA
was digested with
PvuII, transferred onto a nylon
membrane,
and hybridized with WHV DNA. As shown in Fig.
4 and
summarized in Table
1, of the three
woodchucks transfected with
the IIA(

) mutant, the two which gave
positive PCR signals displayed
the characteristic pattern of viral
replicative intermediates
by Southern blotting (Fig.
4, lanes 981 and
4424). However, in
keeping with the serologic results, the signal
strength in these
mutants was strongly reduced compare to that observed
in WT infections
(compare lanes 981 and 4424 with the WT in lane 3278, which were
loaded with comparable amounts of genomic DNA [as revealed
by
ethidium bromide staining in the lower panel]). Taken together,
these results show that while the IIA(

) mutant is indeed replication
competent in vivo, it appears to be less active than its WT parent,
in
contrast to its behavior in HepG2 cells. However, we caution
that this
conclusion is based on a small number of inoculees and
must be
considered provisional.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 4.
Replication of mutant viral genomes in woodchuck liver.
DNA from liver biopsies was digested with PvuII and analyzed
by Southern blot hybridization with a WHV DNA probe. Animal numbers and
corresponding mutants injected are presented above and below the gel,
respectively (upper panel). The lower panel shows ethidium
bromide-stained DNA as a loading control.
|
|
In summary, our results indicate that WHV EnII plays a crucial role in
the regulation of pgRNA but not subgenomic RNA and
that binding of
HNF-1 to the element is indispensable for this
activity. HNF-4 appears
to play a demonstrable but secondary role
in EnII function.
 |
ACKNOWLEDGMENTS |
We thank the National Institutes of Health and the Howard Hughes
Medical Institute for support.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, School of Medicine, University of
California, San Francisco, CA 94143-0502. Phone: (415) 476-2826. Fax:
(415) 476-0939. E-mail: ganem{at}socrates.ucsf.edu.
Present address: Institut Pasteur, 75015 Paris, France.
 |
REFERENCES |
| 1.
|
Cattaneo, R.,
H. Will, and H. Schaller.
1984.
Hepatitis B virus transcription in the infected liver.
EMBO J.
3:2191-2196[Medline].
|
| 1a.
|
Cote, P.,
C. Ronecker,
K. Cass,
F. Schodel,
B. Tennant,
F. deNoronha, and J. Gerin.
1993.
New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection.
Viral Immunol.
6:161-169[Medline].
|
| 2.
|
Di, Q.,
J. Summers,
J. Burch, and W. Mason.
1997.
Major differences between WHV and HBV in the regulation of transcription.
Virology
229:25-35[Medline].
|
| 3.
|
Fourel, G.,
F. Ringeisen,
M. Flajolet,
F. Tronche,
M. Pontoglio,
P. Tiollais, and M.-A. Buendia.
1996.
The HNF1/HNF4-dependent We2 element of woodchuck hepatitis virus controls viral replication and can activate the N-myc2 promoter.
J. Virol.
70:8571-8583[Abstract].
|
| 4.
|
Fourel, G.,
C. Trépo,
L. Bougueleret,
B. Henglein,
A. Ponzetto,
P. Tiollais, and M. A. Buendia.
1990.
Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours.
Nature
347:294-298[Medline].
|
| 5.
|
Ganem, D.
1995.
Hepadnaviridae: the viruses and their replication, p. 2703-2737.
In
B. Fields, et al. (ed.), Virology, vol. 2. Lippincott-Raven, Philadelphia, Pa.
|
| 6.
|
Guo, W.,
M. Chen,
T. S. B. Yen, and J. H. Ou.
1993.
Hepatocyte-specific expression of the hepatitis B virus core promoter depends on both positive and negative regulation.
Mol. Cell. Biol.
13:443-448[Abstract/Free Full Text].
|
| 7.
|
Hansen, L. J.,
B. C. Tennant,
C. Seeger, and D. Ganem.
1993.
Differential activation of myc gene family members in hepatic carcinogenesis by closely related hepatitis B viruses.
Mol. Cell. Biol.
13:659-667[Abstract/Free Full Text].
|
| 8.
|
Kodama, K.,
N. Ogasawara,
H. Yoshikawa, and S. Murakami.
1985.
Nucleotide sequence of a cloned woodchuck hepatitis virus genome: evolutional relationship between hepadnaviruses.
J. Virol.
56:978-986[Abstract/Free Full Text].
|
| 9.
|
Liu, C.,
W. S. Mason, and J. B. E. Burch.
1994.
Identification of factor-binding sites in the duck hepatitis B virus enhancer and in vivo effects of enhancer mutations.
J. Virol.
68:2286-2296[Abstract/Free Full Text].
|
| 10.
|
Loeb, D. D.,
R. C. Hirsch, and D. Ganem.
1991.
Sequence-independent RNA cleavages generate the primers for plus strand DNA synthesis in hepatitis B viruses: implications for other reverse transcribing elements.
EMBO J.
10:3533-3540[Medline].
|
| 11.
|
Lopez-Cabrera, M.,
J. Letovsky,
K. Q. Hu, and A. Siddiqui.
1990.
Multiple liver-specific factors bind to the hepatitis B virus core/pregenomic promoter: trans-activation and repression by CCAAT/enhancer binding protein.
Proc. Natl. Acad. Sci. USA
87:5069-5073[Abstract/Free Full Text].
|
| 12.
|
Popper, H.,
L. Roth,
R. H. Purcell,
B. C. Tennant, and J. L. Gerin.
1987.
Hepatocarcinogenicity of the woodchuck hepatitis virus.
Proc. Natl. Acad. Sci. USA
84:866-870[Abstract/Free Full Text].
|
| 13.
|
Rall, L. B.,
D. N. Standring,
O. Laub, and W. J. Rutter.
1983.
Transcription of hepatitis B virus by RNA polymerase II.
Mol. Cell. Biol.
3:1766-1773[Abstract/Free Full Text].
|
| 14.
|
Seeger, C.,
B. Baldwin, and B. C. Tennant.
1989.
Expression of infectious woodchuck hepatitis virus in murine and avian fibroblasts.
J. Virol.
63:4665-4669[Abstract/Free Full Text].
|
| 15.
|
Shaul, Y.,
W. J. Rutter, and O. Laub.
1985.
A human hepatitis B viral enhancer element.
EMBO J.
4:427-430[Medline].
|
| 16.
|
Siddiqui, A.,
S. Jameel, and J. Mapoles.
1987.
Expression of the hepatitis B virus X gene in mammalian cells.
Proc. Natl. Acad. Sci. USA
84:2513-2517[Abstract/Free Full Text].
|
| 17.
|
Staprans, S.,
D. D. Loeb, and D. Gamen.
1991.
Mutations affecting hepadnavirus plus-strand DNA synthesis dissociate primer cleavage from translocation and reveal the origin of linear viral DNA.
J. Virol.
65:1255-1262[Abstract/Free Full Text].
|
| 18.
|
Su, H., and J. K. Yee.
1992.
Regulation of hepatitis B virus gene expression by its two enhancers.
Proc. Natl. Acad. Sci. USA
89:2708-2712[Abstract/Free Full Text].
|
| 19.
|
Summers, J., and W. S. Mason.
1982.
Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate.
Cell
29:403-415[Medline].
|
| 20.
|
Summers, J.,
J. M. Smolec, and R. Synder.
1978.
A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks.
Proc. Natl. Acad. Sci. USA
75:4533-4537[Abstract/Free Full Text].
|
| 21.
|
Treinin, M., and O. Laub.
1987.
Identification of a promoter element located upstream from the hepatitis B virus X gene.
Mol. Cell. Biol.
7:545-548[Abstract/Free Full Text].
|
| 22.
|
Ueda, K.,
Y. Wei, and D. Ganem.
1996.
Activation of N-myc2 gene expression by cis-acting elements of oncogenic hepadnaviral genomes: key role of enhancer II.
Virology
217:413-417[Medline].
|
| 23.
|
Ueda, K.,
Y. Wei, and D. Ganem.
1996.
Cellular factors controlling the activity of woodchuck hepatitis virus enhancer II.
J. Virol.
70:4714-4723[Abstract].
|
| 24.
|
Wang, Y.,
P. Chen,
X. Wu,
A.-L. Sun,
H. Wang,
Y.-A. Zhu, and Z.-P. Li.
1990.
A new enhancer element, ENII, identified in the X gene of hepatitis B virus.
J. Virol.
64:3977-3981[Abstract/Free Full Text].
|
| 25.
|
Wei, Y.,
G. Fourel,
A. Ponzetto,
M. Silvestro,
P. Tiollais, and M.-A. Buendia.
1992.
Hepadnavirus integration: mechanisms of activation of the N-myc2 retrotransposon in woodchuck liver tumors.
J. Virol.
66:5265-5276[Abstract/Free Full Text].
|
| 26.
|
Will, H.,
W. Reiser,
T. Weimer,
E. Pfaff,
M. Büscher,
R. Sprengel,
R. Cattaneo, and H. Schaller.
1987.
Replication strategy of human hepatitis B virus.
J. Virol.
61:904-911[Abstract/Free Full Text].
|
| 27.
|
Yee, J. K.
1989.
A liver-specific enhancer in the core promoter region of human hepatitis B virus.
Science
246:658-661[Abstract/Free Full Text].
|
| 28.
|
Yuh, C. H., and L. P. Ting.
1993.
Differentiated liver cell specificity of the second enhancer of hepatitis B virus.
J. Virol.
67:142-149[Abstract/Free Full Text].
|
| 29.
|
Yuh, C. H., and L. P. Ting.
1990.
The genome of hepatitis B virus contains a second enhancer: cooperation of two elements within this enhancer is required for its function.
J. Virol.
64:4281-4287[Abstract/Free Full Text].
|
J Virol, August 1998, p. 6608-6613, Vol. 72, No. 8
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Seeger, C., Mason, W. S.
(2000). Hepatitis B Virus Biology. Microbiol. Mol. Biol. Rev.
64: 51-68
[Abstract]
[Full Text]